Innoviva (INVA) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.02 per share a year ago. These figures are ...

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ...

Former chemistry teacher Zhong Huijan’s Hansoh Pharmaceutical Group strikes potentially lucrative licensing deals with big ...

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Google’s parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome ...

Investors have once again turned to Chinese pharmaceutical company Jiangsu Hengrui to create a new biotech startup, this time ...

Biotech firm Bio-Techne missed its first-quarter revenue estimates on Wednesday, hurt by sluggish demand for its products amid soft biotech funding environment in China.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $162.3 million in its third quarter. The Salt Lake City-based company said it had a ...

While investor enthusiasm often focuses on big tech, clinical-stage biotech Recursion Pharmaceuticals (NASDAQ: RXRX) is ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.